Difference between revisions of "Palonosetron (Aloxi)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "[http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or" to "or") |
|||
| (11 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Serotonin 5-HT3 receptor antagonist. Chemotherapy medications and surgery can cause nausea and vomiting by stimulating release of serotonin from the enterochromaffin cells of the small intestine, and serotonin triggers the vomiting reflex by binding to and activating 5-HT3 receptors. Palonosetron prevents nausea and vomiting by binding with high affinity to 5-HT3 receptors and blocking their activation by serotonin.<ref name=insert>[http://www.aloxi.com/docs/pdf/PI.pdf Palonosetron (Aloxi) package insert]</ref><ref>[[ | + | Class/mechanism: Serotonin 5-HT3 receptor antagonist. Chemotherapy medications and surgery can cause nausea and vomiting by stimulating release of serotonin from the enterochromaffin cells of the small intestine, and serotonin triggers the vomiting reflex by binding to and activating 5-HT3 receptors. Palonosetron prevents nausea and vomiting by binding with high affinity to 5-HT3 receptors and blocking their activation by serotonin.<ref name=insert>[http://www.aloxi.com/docs/pdf/PI.pdf Palonosetron (Aloxi) package insert]</ref><ref>[[:File:Palonosetron.pdf | Palonosetron (Aloxi) package insert (locally hosted backup)]]</ref><ref>[http://www.aloxi.com/ Aloxi manufacturer's website]</ref> |
<br>Route: IV | <br>Route: IV | ||
<br>Extravasation: no information available | <br>Extravasation: no information available | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.<ref name="insert"></ref> |
==Patient drug information== | ==Patient drug information== | ||
| Line 11: | Line 11: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * | + | *2003-07-25: Approved for the prevention of acute nausea and vomiting associated with initial and repeat courses of moderately and highly emetogenic cancer chemotherapy and the prevention of delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. |
| − | + | ==History of changes in EMA indication== | |
| + | *2005-03-22: Initial authorization | ||
==Also known as== | ==Also known as== | ||
| − | + | *'''Generic name:''' palonosetron HCL | |
| + | *'''Brand name:''' Aloxi | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| − | [[Category: | + | [[Category:Drugs]] |
| + | [[Category:Intravenous medications]] | ||
[[Category:Emesis prevention]] | [[Category:Emesis prevention]] | ||
[[Category:Serotonin 5-HT3 antagonists]] | [[Category:Serotonin 5-HT3 antagonists]] | ||
| + | |||
| + | [[Category:FDA approved in 2003]] | ||
| + | [[Category:EMA approved in 2005]] | ||
Latest revision as of 00:14, 6 July 2024
General information
Class/mechanism: Serotonin 5-HT3 receptor antagonist. Chemotherapy medications and surgery can cause nausea and vomiting by stimulating release of serotonin from the enterochromaffin cells of the small intestine, and serotonin triggers the vomiting reflex by binding to and activating 5-HT3 receptors. Palonosetron prevents nausea and vomiting by binding with high affinity to 5-HT3 receptors and blocking their activation by serotonin.[1][2][3]
Route: IV
Extravasation: no information available
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.[1]
Patient drug information
- Brief patient counseling information can be found in the Palonosetron (Aloxi) package insert[1]
- Palonosetron (Aloxi) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 2003-07-25: Approved for the prevention of acute nausea and vomiting associated with initial and repeat courses of moderately and highly emetogenic cancer chemotherapy and the prevention of delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.
History of changes in EMA indication
- 2005-03-22: Initial authorization
Also known as
- Generic name: palonosetron HCL
- Brand name: Aloxi